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Epidemiology
Acute leukemias are a heterogeneous group of malignant dis-
eases of hematopoietic progenitor cells with different molecular
genetic abnormalities, clinical characteristics, and variable out-
comes with currently available treatments. Age-specific inci-
dence of acute myeloid leukemia (AML) rises linearly after age
40 with a median age of approximately 65 years. Most cases
are sporadic, but congenital disorders such as Fanconi’s,
Bloom’s, Down’s, Kostmann’s, and Diamond-Blackfan syn-
dromes can increase the relative risk of developing AML
(Scheinberg et al., 2001). Risk is also increased in individuals
with acquired hematologic disorders including the myeloprolifer-
ative and myelodysplastic syndromes and paroxysmal noctur-
nal hemoglobinuria. Therapy-related AML (t-AML) may develop
as a consequence of exposure to chemotherapy, including alky-
lating agents, epipodophyllotoxins, and ionizing radiation
(Scheinberg et al., 2001). The age-specific incidence of acute
lymphoblastic leukemia (ALL) peaks between the ages of 2 and
4, declines during late childhood adolescence and young adult-
hood, and peaks again among older adults. Mortality from ALL
has declined dramatically during the last 25 years due to
improvements in chemotherapy, particularly among children.
Classification, diagnosis, and prognosis
The French-American-British (FAB) classification, described
approximately 25 years ago, remains the foundation on which the
morphologic diagnosis of AML and ALL is based. However, the
new World Health Organization (WHO) classification takes into
account cytogenetics, molecular genetics, and morphologic and
immunophenotypic findings not previously described (Harris et
al., 1999).The diagnosis of AML is now established when at least
20% of the cells identified in the blood or bone marrow are blasts
of myeloid origin. Precursor B cell acute lymphoblastic leukemia
is now defined by cytogenetic and molecular genetic subgroups
since these impart important prognostic information.
Diagnosis of acute leukemias requires morphologic evalua-
tion of the peripheral blood smear, bone marrow aspirate and
core biopsy, cytogenetics, molecular genetics, and immunophe-
notyping. The latter is particularly important in the subclassifica-
tion of patients with ALL. In AML patients, cytogenetics are impor-
tant prognostic factors in predicting response to treatment
(Grimwade et al., 1998; Mrozek et al., 2000). Patients with AML
whose leukemic cells have translocations t(8;21), t(15;17),
t(16;16), or inv(16) have a favorable outcome with induction
chemotherapy and intensive postremission consolidation
chemotherapy. However, abnormalities of chromosomes 5 or
7,11q23 or complex karyotypes have a very poor outcome with
currently available induction and postremission chemotherapy.
Patients with a normal karyotype or with trisomy 8 have an inter-
mediate prognosis. Among adults with ALL, t(9;22) or t(4;11) con-
fer a very poor prognosis. Patients with t(9;22) ALL are rarely, if
ever, cured with chemotherapy alone. The immunophenotypic
determination of surface antigens expressed on leukemic blast
cells may aid in diagnosis and has important implications for
treatment and prognosis of myeloid, T, and B lineage leukemias.
FISH, SKY, CGH, MRD monitoring, and DNA microarrays
New techniques have begun to revolutionize diagnosis, progno-
sis, and classification of leukemias. Fluorescence in situ
hybridization (FISH) allows for rapid testing for specific chromo-
somal translocations in both metaphase and interphase cells.
Spectral karyotyping (SKY) uses 24 different fluorescently
labeled chromosome painting probes to generate automated
color display of all chromosomes, enhancing accuracy and sen-
sitivity of cytogenetic analysis, especially with complex kary-
otypes. Comparative genomic hybridization (CGH) provides a
sensitive method for identification of regions of genomic dele-
tion or amplification and may identify new disease genes at
these loci. Minimal residual disease (MRD) monitoring using
sensitive RT-PCR-based amplification and quantitation of fusion
genes may be useful to predict relapse. Finally, DNA microarray
analysis of gene expression profiles may enhance conventional
diagnostic and prognostic testing. For example, expression
arrays can delineate AML versus ALL samples based solely on
patterns of gene expression (Golub et al., 1999). Furthermore,
expression array analysis has demonstrated that ALL associat-
ed with MLL translocations is a distinct subtype of acute
leukemia, readily distinguished from either AML or ALL
(Armstrong et al., 2002). In addition, expression profiling is a
valuable tool for classification, subtype discovery, and predic-
tion of outcome in pediatric B and T lymphoid leukemias
(Ferrando et al., 2002;Yeoh et al., 2002).
Disease mechanisms and molecular targets
Chromosomal translocations
Cloning of recurring chromosomal translocation breakpoints
associated with acute leukemias has provided valuable insights
into disease mechanisms, as well as identification of therapeu-
tic targets. More than 100 have been cloned, and although
genotypically diverse, many translocations target similar signal
transduction and transcriptional activation pathways. For exam-
ple, acute promyelocytic leukemia (APL) is associated with
t(15;17)(q22;q12) giving rise to the PML/RARα fusion, but the
same phenotype is observed with at least four other chromoso-
mal translocations involving the RARα gene. PML/RARα is a
dominant-negative inhibitor of transcription through aberrant
recruitment of the nuclear corepressor complex (NCoR), includ-
ing histone deacetylase (HDAC). Patients with acute promyelo-
cytic leukemia (APL) respond dramatically to the differentiating
effects of all-trans retinoic acid (ATRA) (Fenaux et al., 1999;
Tallman et al., 1997). ATRA binding to the PML/RARα fusion
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results in release of NCoR and restoration of normal transcrip-
tional differentiation programs. The clinical success of “differen-
tiation” therapy has stimulated enthusiasm for identification of
other agents that target the NCoR complex, including HDAC
inhibitors (Figure 1).
The AML1 and CBFβ components of the heterodimeric
transcription factor core binding factor (CBF) are targeted by a
dozen different translocations and result in loss of function of
CBF. These include the t(8;21)(q22;q22) and inv(16)(p13q22)
that result in expression of the AML1/ETO and CBFβ/SMMHC
fusions and account for about 20%–25% of adult AML. The
TEL/AML1 fusion in t(12;21)(p13;q22) pediatric ALL accounts
for about 25% of childhood ALL. CBF is essential for normal
hematopoietic development, and translocations involving CBF
result in expression of dominant-negative inhibitors of CBF
(Okuda et al., 1998; Yergeau et al., 1997). Like PML/RARα,
dominant-negative activity of CBF fusions is mediated by aber-
rant recruitment of the NCoR/HDAC complex, suggesting that
differentiation therapy with HDAC inhibitors might also be effec-
tive in this group of leukemias. Other transcription factors that
are important in normal hematopoietic development are also
targeted by translocations, including HOX family members and
transcriptional regulatory and coactivating proteins such as
MLL, CBP, p300, and TIF2 (Mrozek et al., 2000).
Rare cases of pediatric ALL and about 30% of adult ALL
harbor t(9;22)(q34;q11) giving rise to the BCR/ABL fusion. In
addition, the MLL-AF4 fusion associated with t(4;11)(q21;q23)
occurs in the majority of cases of infant ALL, and this distinct
clinical entity is associated with overexpression of FLT3
(Armstrong et al., 2002).
Point mutations
Point mutations also play an important role in pathogenesis of
acute leukemia. Activating mutations have been identified in
RAS (20%), FLT3 (30%–35%), and c-KIT (5%) as well as loss of
function mutations in the hematopoietic transcription factors
AML1 and C/EBPα.
Deletions
Identification of the gene(s) responsible for acute leukemias asso-
ciated with recurrent deletions, including 5q−, 7q−, and 20q−, has
been difficult. Efforts have focused on identification of classical
tumor suppressor genes at these loci, in which there is loss of
function of one allele due to deletion and of the other due to muta-
tion. The lack of success thus far and recent observations that
half gene dosage can contribute to hematopoietic phenotype
suggest that haploinsufficiency of one or more genes in the delet-
ed regions may contribute to the leukemic phenotype.
Cooperating mutations in acute leukemia
No single mutation is sufficient to cause acute leukemia. For
example, expression of PML/RARα, AML1/ETO, or inv(16) alone
impairs hematopoietic development and may contribute to expan-
sion of the stem cell pool but is not sufficient to cause acute
leukemia (Castilla et al., 1999; Grisolano et al., 1997; He et al.,
1997; Higuchi et al., 2002). Similarly, expression of BCR/ABL,
activated RAS, or activated FLT3 can cause myeloproliferative
disease (Kelly et al., 2002a) but is not sufficient to cause acute
leukemia. Accumulating experimental and epidemiologic evi-
dence suggests a model of cooperation between two classes of
mutations in acute leukemia (Dash and Gilliland, 2001). One
class of mutations, exemplified by activating mutations in RAS,
FLT3, or KIT, confers a proliferative and/or survival benefit to
hematopoietic progenitors but does not affect differentiation. A
second class of mutations, exemplified by PML/RARα,
AML1/ETO, HOX gene fusions or MLL gene rearrangements,
impairs hematopoietic differentiation and may contribute to
expansion of hematopoietic progenitors (Figure 1). Acute
leukemia, characterized by enhanced proliferation and survival of
cells and impaired differentiation, is the consequence of expres-
sion of both classes of mutations. One important implication of
this hypothesis is that there may be therapeutic synergy achieved
by targeting each class of mutation, such as a combination of
FLT3 inhibitors and ATRA in treatment of APL.
Current therapeutic strategies
During the past 40 years, treatment for both AML and ALL has
been based on empirically derived cytotoxic chemotherapy. The
best treatment for the majority of adults with AML, except those
with APL, includes induction chemotherapy with an anthracycline
or anthracenedione plus cytarabine followed by multiple cycles of
intensive postremission chemotherapy, usually with high-dose
cytarabine (Mayer et al., 1994). Patients with CBF leukemias
[t(8;21) and inv(16) or t(16;16)] have an excellent outcome with
this strategy, and a five-year disease-free survival (DFS) of
60%–70% has been achieved (Bloomfield et al., 1998).
Randomized clinical trials have not shown any benefit for the
Figure 1. Pathogenesis and treatment of acute
leukemias
As indicated by the yellow star, intensive cyto-
toxic chemotherapy remains the mainstay of
treatment for all acute leukemias. Good prog-
nosis leukemias are indicated in blue, poor
prognosis leukemias are in red, and intermedi-
ate or unknown are in white. There are two
classes of cooperating mutations in acute
leukemia, those that confer proliferation
and/or survival and those that impair
hematopoietic differentiation. Targeted thera-
pies have been developed or are being tested
for many of these, including ATRA, arsenic, and
HDAC inhibitors for APL associated with the
PML/RARα fusion. HDAC inhibitors may also
have utility for treating core binding factor
leukemias such as AML1/ETO. STI571 (Gleevec,
imatinib) is a selective inhibitor of BCR/ABL
tyrosine kinase activity and has activity in CML
blast crisis and in BCR/ABL-positive ALL. STI571
may also have activity in leukemias with acti-
vating mutations in c-KIT, although the most common of these, D816Y, is STI571 resistant. FLT3 inhibitors and farnesyl transferase inhibitors are also being
tested in acute leukemia associated with FLT3 (Kelly et al., 2002b; Weisberrg et al., 2002 [both this issue of Cancer Cell]) and RAS mutations, respectively.
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addition of other agents or high-dose cytarabine in induction
(Buchner et al., 1999). With the exception of the CBF leukemias,
which have the most favorable outcome with at least three cours-
es of intensive high-dose cytarabine as postremission
chemotherapy, the optimal number of courses has not been
determined. Older adults (≥55–60) do not benefit from intensive
postremission chemotherapy following successful induction
(Mayer et al., 1994).The most curable subtype of AML in adults is
APL. The important advance is the incorporation of ATRA in
induction and maintenance therapy, and five-year DFS of
75%–85% is now anticipated (Figure 2; Fenaux et al., 1999;
Tallman et al., 1997). In patients with AML, attempts to exploit
potential graph-versus-leukemia effect have yielded moderate
success. Although hematopoietic stem cell transplantation
(HSCT) from a human leukocyte antigen (HLA)-matched sibling
donor is associated with the most potent antileukemic effect,
treatment-related mortality remains approximately 20%, offset-
ting the benefits of the antileukemic effect in historical random-
ized clinical trials (Cassileth et al., 1998). However, this approach
may be the only curative one for patients who fail induction or
have unfavorable cytogenetics (Slovak et al., 2000). Similarly, in
prospective randomized trials during the last decade, autologous
HSCT has not consistently led to a better outcome than intensive
postremission chemotherapy in randomized trials but may offer
an advantage following multiple cycles of intensive postremission
chemotherapy (Burnett et al., 1998). Low-intensity nonmyeloabla-
tive HSCT attempts to decrease the intensity of chemotherapy
and increase immunosuppression in order to minimize toxicity
and permit a graft-versus-tumor effect (Giralt et al., 1997).
Haploidentical HSCT is a promising strategy, although profound
immunosuppression with late opportunistic infections remains
problematic (Aversa et al., 1998).
The principal phases of treatment for adults with ALL include
remission induction with a vincristine-prednisone-based regimen
and an anthracycline, multiple postremission cycles of
chemotherapy variously designated as intensification or consoli-
dation, with a variety of agents including high-dose methotrexate,
high-dose cytarabine, alkylating agents, epipodophyllotoxins, L-
asparaginase, central nervous system (CNS) treatment or pro-
phylaxis, and maintenance therapy with vincristine and pred-
nisone-based chemotherapy (Larson et al., 1995). Approximately
35% of adults with ALL are alive and free of disease at 5 years
and beyond in large cooperative group trials. Historically,
although HLA-matched sibling allogeneic HSCT has been
reserved for patients at high risk of recurrence, contemporary
studies suggest a benefit in all risk groups when carried out in first
complete remission. The role of autologous HSCT has not been
established and remains an area of investigation.
Recent advances in therapy
Insights into molecular pathogenesis have led to development
of a spectrum of new targeted therapies for leukemia.
Gemtuzumab ozogamicin, an anti-CD33 monoclonal antibody
chemically linked to the potent cytotoxic agent calicheamicin,
has activity in CD33-positive AML (Sievers et al., 2001). Arsenic
trioxide has potent activity in APL, in part through effects on
PML/RARα stability and through induction of apoptosis
(Soignet et al., 2001). STI571 (Gleevec, imatinib mesylate), a
small-molecule inhibitor of the ABL kinase, has activity in CML,
CML blast crisis, and in BCR/ABL-positive ALL. Farnesyl trans-
ferase inhibitors (FTIs) impair prenylation and targeting of RAS
to the plasma membrane and are being tested in AML patients
with activating mutations in RAS. In addition, because BCR/ABL
activates RAS, FTIs are being tested in concert with imatinib 
in BCR/ABL-positive leukemias and in imatinib-resistant
leukemias. Activated FLT3 is an exceptionally attractive target for
therapy as the single most commonly mutated gene in AML and
is associated with a poor prognosis (Kottaridis et al., 2001).
Selective inhibitors of FLT3 (Kelly et al., 2002b; Weisberg et al.,
2002 [both in this issue of Cancer Cell]) have been developed
and are entering clinical trials in AML. HDAC inhibitors are cur-
rently being tested in AML in an attempt to induce differentiation
and apoptotic cell death, analogous to the effect of ATRA in APL.
Future challenges
Progress toward cure of acute leukemia is likely to occur with new
therapies directed at specific molecular targets, such as
BCR/ABL, FLT3, RAS, and the NCor/HDAC complex. This goal
may be facilitated by modern genomic approaches to acute
leukemia, including use of DNA microarray and proteomic strate-
gies for identification of novel targets and prognostic indicators. In
addition, to the extent that molecularly targeted therapies are
effective, resistance mechanisms will develop that must be
addressed and circumvented. Successful solutions to these chal-
lenges will require continued cooperation between laboratory sci-
entists and clinical investigators and improved accrual to clinical
trials evaluating the benefits of new targeted treatments.
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